The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Lung Cancer Research Program -- Investigator-Initiated Translational Research Award
The FY22 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. Research applications only in the area of mesothelioma will not be accepted. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.
• Required Pre-Application Deadline: May 4, 2022
• Invitation to Submit an Application: June 2022
• Application Submission Deadline: July 27, 2022
Areas of Interest
To be considered for funding, applications for the FY22 LCRP Investigator-Initiated Translational Research Award must address at least one of the Areas of Emphasis listed below: • Identify innovative strategies for prevention of the occurrence of lung cancer. • Identify innovative strategies for the screening and early detection of lung cancer. • Understand the molecular mechanisms of initiation and progression to lung cancer. • Understand contributors to lung cancer development other than tobacco. • Identify innovative strategies for the treatment of lung cancer. • Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer. • Develop or optimize biomarkers to assist with therapeutic decision-making. • Understand mechanisms of resistance to treatment (primary and secondary). • Identify innovative strategies for comprehensive lung cancer care (clinical management/ surveillance/symptom management/palliative care). • Understand factors and/or develop implementation strategies to address health disparities in lung cancer.
Principal Investigator (PI) must be at or above the level of Assistant Professor (or equivalent). An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY22 LCRP Investigator-Initiated Translational Research Award will not exceed $600,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.